BLOG

How Does Stem Cell IV Infusion Work? Understanding the Homing Effect

Published 2026.10.09 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

When people first read about adipose-derived stem cell therapy, one detail often raises questions: the cells are given through an ordinary intravenous (IV) drip. How can cells delivered into a vein support tissues elsewhere in the body? This article explains the basic idea, what researchers mean by the “homing effect,” and what remains uncertain, so you can have a more informed conversation with a doctor.

The short answer

In this treatment, mesenchymal stem cells taken from a small amount of your own fat tissue are cultured and expanded at a specialized facility, then returned to your body by IV infusion. Laboratory and clinical research suggests that these cells may move through the bloodstream and may release substances that influence inflammation and tissue repair. However, how much of this happens in each person, and how it translates into clinical benefit, varies and is still being studied. Results cannot be promised, and any decision should rest on an individual consultation with a physician.

Why an IV drip is used

An IV infusion is a familiar, minimally invasive way to deliver a treatment to the whole body. Instead of targeting a single spot, the cultured cells enter the circulation and can be carried throughout the body. This is why the approach is sometimes described as a whole-body method, in contrast with local injections aimed at one joint or one area.

Because the cells are your own (autologous), the chance of rejection is generally considered lower than with donor cells. That does not mean the infusion is free of risk. Reactions during or after infusion, infection risk related to the procedure, and individual factors can all matter, which is why a medical history review is an important part of any consultation.

What is the homing effect?

“Homing” describes the observation that mesenchymal stem cells can be attracted toward areas of inflammation or tissue damage. Injured tissue releases chemical signals, and cells in the bloodstream may respond to those signals and gather near the affected site. Research in this area has been reported for many years, and it is one reason mesenchymal stem cells attract attention in regenerative medicine.

It is important to read this concept carefully. Studies of cells after intravenous infusion have found that a notable share of cells can initially become trapped in the lungs, and that many cells do not persist for long. Researchers therefore also discuss a second mechanism: the cells may act mainly through the anti-inflammatory molecules and growth factors they secrete, rather than by physically replacing damaged tissue. Both ideas are active areas of investigation, and neither should be understood as a promise of a particular outcome.

From fat collection to infusion: the overall flow

The process begins with a consultation, followed by a small collection of fat tissue under local anesthesia on an outpatient basis. Only a very small amount is needed. The mesenchymal stem cells contained in the tissue are then isolated and cultured at a specialized facility, where their number is expanded over a period of time. Once the culture is ready, the cells are returned to you by IV infusion, also as an outpatient visit.

Because culture takes time, the collection visit and the infusion visit are separated. International patients in particular should ask how the schedule works, how many visits are expected, and how follow-up will be handled if they return home between visits.

How the treatment is regulated in Japan

In Japan, this type of cell therapy is provided under a regenerative medicine provision plan submitted in accordance with the Act on the Safety of Regenerative Medicine. The plan is reviewed by a certified committee and submitted to the Ministry of Health, Labour and Welfare, and cell processing is carried out at registered facilities. This framework sets procedural requirements, but it does not by itself establish that a treatment works for a specific condition.

This treatment is also a self-pay (uninsured) medical service, which means health insurance generally does not cover it. Costs, the number of infusions, possible risks and side effects, and whether the therapy is suitable for you should all be confirmed directly with a doctor.

Questions to ask before you decide

Grand Green Osaka Umekita Clinic, located in Umeda, Osaka, offers adipose-derived stem cell therapy and provides information pages for international patients in several languages. Whichever clinic you consider, the following questions can help you prepare for a consultation:

What is the goal of treatment for my situation, and what is the evidence behind it?
What risks and side effects are possible, and how are they monitored and managed?
How many visits are involved, and what does the full fee cover?
How does this relate to standard treatments I am already receiving or could receive?
What follow-up is available after I return home?

Stem cell therapy should not be seen as a replacement for standard medical care. A clear, unhurried discussion with a physician about your health, your expectations, and the uncertainties is the best starting point.

Summary

IV infusion delivers cultured mesenchymal stem cells into the bloodstream, which can carry them through the body. The homing effect describes how these cells may be drawn toward inflamed or damaged areas, while other research points to the substances the cells release as an important part of their action. Evidence is still developing, individual responses differ, and the therapy is a self-pay treatment provided under Japan’s regenerative medicine framework. If you are considering it, a consultation with a doctor is the right place to review benefits, risks, costs, and whether it fits your circumstances.

From Fat Collection to Infusion

1ConsultationDoctor reviews your history
2Fat collectionLocal anesthesia, outpatient
3Cell cultureExpanded at a specialized facility
4IV infusionOutpatient visit

This diagram is a conceptual summary of the article and does not promise any result

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›